Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Bullboard Posts
Comment by Garp1on Jun 18, 2010 8:43am
381 Views
Post# 17200998

RE: SP manipulation at its best!

RE: SP manipulation at its best!A bit far fetched, I don't think that Rosconi retirement or that Bozo the share seller clown (Don't forget that management gave him those options so he could dump those shares!!!!!!!!) are making the difference.

But one could imagine that if you wanted to buy this company in the near futur, it would be tempting to make sure the price of the share is kept low (lets say $5) so that you could make a bid of $7.5 per share (50% premium). This could certainly be attractive  to a lot of shareholders and would probably cost no more then short selling about 1 million to 2 million shares at a lost of $1 per share, which comes out to about 1 to 2 million dollars. 
 
On the other hand, letting the price move upwards (lets say to $7) could entail having to pay  $10.50 on a buyout and that would represent having to dish out $2.50 more a share on 60 million shares.

The first option costs 1 to 2 millions, the second options cost 150 millions more.
Bullboard Posts